CIK 0001472012
- Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 770694340
- Phone
- +1 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-08 | Lefenfeld Michael Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | LAMATTINA JOHN L Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | BARON RICHARD A Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | PRENDERGAST FRANKLYN G Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | WAGENHEIM PHILIP Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | Giesing Dennis H Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-01-15 | WAGENHEIM PHILIP Director | Grant or award | +8,750 | $4.00 | $35K | 406,147 |
| 2023-01-15 | LAMATTINA JOHN L Director | Grant or award | +15,125 | $4.00 | $61K | 66,953 |
| 2023-01-15 | Lefenfeld Michael Director | Grant or award | +13,875 | $4.00 | $56K | 40,747 |
| 2023-01-15 | RAPP MICHAEL Director | Grant or award | +17,500 | $4.00 | $70K | 817,366 |
| 2022-06-16 | Stoneman Sandra G. General Counsel and CLO | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 | ||
| 2022-06-16 | Sarma Purnanand D President and CEO | Grant or award · Stock Option (Right to Buy) | +121,000 | 121,000 | ||
| 2022-06-16 | Roche Corleen M. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2022-06-16 | ROBINSON MATTHEW K Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2022-06-16 | Giesing Dennis H Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-06-16 | WAGENHEIM PHILIP Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2022-06-16 | RAPP MICHAEL Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2022-06-16 | PRENDERGAST FRANKLYN G Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2022-06-16 | Lefenfeld Michael Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2022-06-16 | LAMATTINA JOHN L Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 |
Page 9 of 12 · 240 trades